RAMB - Julho 2016

14 / 99

Collange NZ et al.
302 Rev Assoc Med Bras 2016; 62(4):298-302
9. Wang KC, Lee JI, Cho BK, Kim IH, Kim JY, Shin HY, et al. Treatment outcome
and prognostic factors of medulloblastoma. J KoreanMed Sci. 1994; 9(1):64-73.
10. Monteith SJ, Heppner PA, Woodfield MJ, Law AJ. Paediatric central nervous
systemtumoursinaNewZealand
management strategies and outcomes. J ClinNeurosci. 2006; 13(7):722-9.
11. Fried I, Huang A, Bartels U, Tabori U, Laperriere N, Dirks P, et al. Chronic
residual lesions in metastatic medulloblastoma patients. J Pediatr Hematol
Oncol. 2014; 36(1):71-5.
12. Kombogiorgas D, Puget S, Boddaert N, Peet A, English M, Natarajan K, et
al. Appraisal of the current staging system for residual medulloblastoma
by volumetric analysis. Childs Nerv Syst. 2011; 27(12):2101-6.
13. Ranger A, McDonald W, Bauman GS, Del Maestro R. Effects of surgical
excision and radiation on medulloblastoma cell invasiveness. Can J Neurol
Sci. 2009; 36(5):631-7.
14. Schubert MI, Wilke M, Müller-Weihrich S, Auer DP. Diffusion-weighted
magnetic resonance imaging of treatment-associated changes in recurrent
and residual medulloblastoma: preliminary observations in three children.
Acta Radiol. 2006; 47(10):1100-4.
15. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al.
Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors
for medulloblastoma in children: conclusions from the Children’s Cancer
Group 921 randomized phase III study. J Clin Oncol. 1999; 17(3):832-45.
16. Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects
of medulloblastoma resections on outcome in children: a report from the
Children’s Cancer Group. Neurosurgery. 1996; 38(2):265-71.
17. Sure U, Berghorn WJ, Bertalanffy H, Wakabayashi T, Yoshida J, Sugita K, et
al. Staging, scoring and grading of medulloblastoma. A postoperative
prognosis predicting system based on the cases of a single institute. Acta
Neurochir (Wien). 1995; 132(1-3):59-65.
18. Patrice SJ, Tarbell NJ, Goumnerova LC, Shrieve DC, Black PM, Loeffler JS.
Results of radiosurgery in the management of recurrent and residual
medulloblastoma. Pediatr Neurosurg. 1995; 22(4):197-203.
19. Bourne JP, Geyer R, Berger M, Griffin B, Milstein J. The prognostic significance
of postoperative residual contrast enhancement on CT scan in pediatric
patients with medulloblastoma. J Neurooncol. 1992; 14(3):263-70.
20. Korah MP, Esiashvili N, Mazewski CM, Hudgins RJ, Tighiouart M, Janss AJ,
et al. Incidence, risks, and sequelae of posterior fossa syndrome in pediatric
medulloblastoma. Int J Radiat Oncol Biol Phys. 2010; 77(1):106-12.
21. Kombogiorgas D, Natarajan K, Sgouros S. Predictive value of preoperative
ventricular volume on the need for permanent hydrocephalus treatment
immediately after resection of posterior fossa medulloblastomas in children.
J Neurosurg Pediatr. 2008; 1(6):451-5.
22. Hoffman HJ, Hendrick EB, Humphreys RP. Metastasis via ventriculoperitoneal
shunt in patients with medulloblastoma. J Neurosurg. 1976; 44(5):562-6.
23. Muzumdar DP. Ventricular CSF drainage and medulloblastoma. Ped
Neurosurg. 2007; 43(1):74-5.
24. Due-Tønnessen BJ, Helseth E. Management of hydrocephalus in children
with posterior fossa tumors: role of tumor surgery. Pediatr Neurosurg. 2007;
43(2):92-6.
25. Gopalakrishnan CV, Dhakoji A, Menon G, Nair S. Factors predicting the
need for cerebrospinal fluid diversion following posterior fossa tumor
surgery in children. Pediatr Neurosurg. 2012; 48(2):93-101.
26. Kumar V, Phipps K, Harkness W, Hayward RD. Ventriculo-peritoneal shunt
requirement in children with posterior fossa tumours: an 11-year audit. Br
J Neurosurg. 1996; 10(5):467-70.
27. Morelli D, Pirotte B, Lubansu A, Detemmerman D, Aeby A, Fricx C, et al.
Persistent hydrocephalus after early surgical management of posterior fossa
tumors in children: is routine preoperative endoscopic third ventriculostomy
justified? J Neurosurg. 2005; 103(3 Suppl):247-52.
28. Lee M, Wisoff JH, Abbott R, Freed D, Epstein FJ. Management of
hydrocephalus in children with medulloblastoma: prognostic factors for
shunting. Pediatr Neurosurg. 1994; 20(4):240-7.
29. El-Ghandour NM. Endoscopic third ventriculostomy versus ventriculoperitoneal
shunt in the treatment of obstructive hydrocephalus due to posterior fossa
tumors in children. Childs Nerv Syst. 2011; 27(1):117-26.
30. Bouffet E, Bernard JL, Frappaz D, Gentet JC, Roche H, Tron P, et al. M4
protocol for cerebellar medulloblastoma: supratentorial radiotherapy may
not be avoided. Int J Radiat Oncol Biol Phys. 1992; 24(1):79-85.
31. Lafay-Cousin L, Bouffet E, Hawkins C, Amid A, Huang A, Mabbott DJ.
Impact of radiation avoidance on survival and neurocognitive outcome in
infant medulloblastoma. Curr Oncol. 2009; 16(6):21-8.
32. Rutkowski S, Gerber NU, von Hoff K, Gnekow A, Bode U, Graf N, et al.;
German Pediatric Brain Tumor Study Group. Treatment of early childhood
medulloblastoma by postoperative chemotherapy and deferred radiotherapy.
Neuro Oncol. 2009; 11(2):201-10.
33. Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, et al.
Hyperfractionated versus conventional radiotherapy followed by
chemotherapy in standard-risk medulloblastoma: results from the
randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol. 2012;
30(26):3187-93.
34. Christopherson KM, Bradley JA, Rotondo RL, Pincus DW, Fort JA, Morris
CG, et al. Local control in non-metastatic medulloblastoma. Acta Oncol.
2014; 3:1-7.
35. Pichandi A, Ganesh KM, Jerrin A, Balaji K, Sridhar PS, Surega A. Cranio
spinal irradiation of medulloblastoma using high precision techniques – A
dosimetric comparison. Technol Cancer Res Treat. 2014. [Epub ahead of
print]